1.40 USD
▲+0.01+0.72%
盘后 1.69 0.00%
2026-11-20
市值
$75.28M
市盈率
—
EPS
-0.77
股息率
—
52 周区间
1.35 – 4.06
成交量
61.43K
Beta
3.46
目标价
11.00
52W 低 1.3552W 高 4.06
价格走势
公司简介
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company’s lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey...